Expression of CCDC69 in breast cancer and its clinical significance
LIU Xiansheng1, WANG Zhenguo2, GAO Wenjie1, YU Xiaoshuang1, and REN Guibing3
1.Logistics University of People’s Armed Police Force,Tianjin 300309,China; 2.Department of Medical Research, 3.Department of Oncology,Characteristic Medical Center of People’s Armed Police Force,Tianjin 300162,China
Abstract：Objective To investigate the expression of CCDC69 in breast cancer and its association with clinical features and prognosis of breast cancer patients, and to predict the role of CCDC69 in the development of breast cancer.Methods Breast cancer datasets were downloaded from the cancer genome atlas (TCGA) to obtain the CCDC69 gene expression profiles and clinical information. The expression levels of CCDC69 in breast cancer tissues and normal breast tissues were compared, and the correlations of CCDC69 expression levels with clinicopathological parameters and their impact on prognosis were analyzed. Gene enrichment analysis (GSEA) was used to predict the possible pathways regulated by CCDC69 in breast cancer.Results CCDC69 in breast cancer tissues was under-expressed compared with normal breast tissues (P<0.001),and low expression of CCDC69 was an independent risk factor affecting the prognosis of patients with breast cancer. CCDC69 expressions were associated with age (P=0.020) and tumor size (P=0.027). The overall survival of patients with low expressions of CCDC69 was shorter than that of patients with high expressions of CCDC69 (P=0.004). CCDC69 was negatively correlated with MYC signaling pathway, E2F signaling pathway, unfolded protein response and glycolysis gene sets.Conclusions CCDC69 may play a role as a tumor suppressor gene involved in the occurrence and development of breast cancer, and it can be potentially used as a therapeutic target and prognostic indicator.
刘显胜, 王振国, 高温杰, 于晓双, 任贵兵. CCDC69在乳腺癌中的表达及其临床意义[J]. 武警医学, 2019, 30(10): 890-893.
LIU Xiansheng, WANG Zhenguo, GAO Wenjie, YU Xiaoshuang, and REN Guibing. Expression of CCDC69 in breast cancer and its clinical significance. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(10): 890-893.
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424.
[2]
Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer,2019, 144(8): 1941-1953.
[3]
Yip C H, Evans D G, Agarwal G, et al. Global disparities in breast cancer genetics testing, counselling and management[J]. World J Surg, 2019,43(5):1264-1270.
[4]
Abdel F T, Agarwal D, Liu D X, et al. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis[J]. Lancet Oncol, 2016,17(7):1004-1018.
Eriksson L, Bergh J, Humphreys K, et al. Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A population-based cohort study[J]. Int J Cancer, 2018,143(5):1093-1104.
Yin D T, Xu J, Lei M, et al. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma[J]. Oncotarget,2016,7(5): 5830-5841.
[9]
Jiang G Y, Zhang X P, Zhang Y, et al. Coiled-coil domain-containing protein 8 inhibits the invasiveness and migration of non-small cell lung cancer cells[J]. Hum Pathol,2016,56: 64-73.
[10]
Wei S, Shang H, Cao Y, et al. The coiled-coil domain containing protein Ccdc136b antagonizes maternal Wnt/β-catenin activity during zebrafish dorsoventral axial patterning[J]. J Genet Genomics,2016,43(7):431-438.
Pal D, Wu D, Haruta A,et al. Role of a novel coiled-coil domain-containing protein CCDC69 in regulating central spindle assembly[J]. Cell Cycle, 2010,9(20): 4117-4129.
[13]
Cui L, Zhou F, Chen C, et al. Overexpression of CCDC69 activates p14ARF/MDM2/p53 pathway and confers cisplatin sensitivity[J]. J Ovarian Res, 2019,12(1): 4-11.
[14]
Dillies M A, Rau A, Aubert J, et al. A comprehensive evaluation of normalization methods for Illumina high-throughput RNA sequencing data analysis[J]. Brief Bioinform,2013,14(6): 671-683.
[15]
Robinson M D, Mccarthy D J, Smyth G K. EdgeR: a bioconductor package for differential expression analysis of digital gene expression data[J]. Bioinformatics, 2010,26(1): 139-140.
[16]
Veeraraghavan J, Tan Y, Cao X X, et al. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers[J]. Nat Commun, 2014,5(1):4577-4588.
Khan F M, Marquardt S, Gupta S K, et al. Unraveling a tumor type-specific regulatory core underlying E2F1 mediated epithelial-mesenchymal transition to predict receptor protein signatures[J]. Nat Commun,2017,8(1):198-212.
[20]
Sisinni L, Pietrafesa M, Lepore S, et al. Endoplasmic reticulum stress and unfolded protein response in breast cancer: the balance between apoptosis and autophagy and its role in drug resistance[J]. Int J Mol Sci,2019,20(4):857-873.
2019, Vol. 30 
